Inovio
A US biotech focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people from diseases associated with HPV, cancer, and infectious diseases.
Inovio's most advanced clinical program, VGX-3100, is in Phase III development for the treatment of HPV-related cervical pre-cancer.
Also in development are Phase II immuno-oncology programs targeting HPV-related cancers and glioblastoma multiforme, as well as externally-funded platform development programs in Zika, MERS, Lassa, and HIV.
Partners and collaborators include ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations and many more.
Latest Inovio News & Features
18 November 2022
11 May 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze